Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

In a recent study, we described the neuroprotective properties of VCE-003.2—an aminoquinone derivative of the non-psychotropic phytocannabinoid cannabigerol (CBG)—administered intraperitoneally (i.p.) in an inflammatory model of Parkinson’s disease (PD). We also demonstrated that these properties de...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Molecules
Main Authors: Burgaz, Sonia, García, Concepción, Gómez-Cañas, Maria, Muñoz, Eduardo, Fernández-Ruiz, Javier
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6696432/
https://ncbi.nlm.nih.gov/pubmed/31349553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules24152702
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares